- Home
- TLSA vs HLVX Comparison
TLSA vs HLVX Comparison
Compare TLSA & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSA
- HLVX
- Stock Information
- Founded
- TLSA 2013
- HLVX 2020
- Country
- TLSA United Kingdom
- HLVX United States
- Employees
- TLSA N/A
- HLVX N/A
- Industry
- TLSA Biotechnology: Pharmaceutical Preparations
- HLVX Biotechnology: Pharmaceutical Preparations
- Sector
- TLSA Health Care
- HLVX Health Care
- Exchange
- TLSA Nasdaq
- HLVX Nasdaq
- Market Cap
- TLSA 187.0M
- HLVX 83.7M
- IPO Year
- TLSA 2000
- HLVX 2022
- Fundamental
- Price
- TLSA $1.44
- HLVX $2.13
- Analyst Decision
- TLSA
- HLVX Hold
- Analyst Count
- TLSA 0
- HLVX 5
- Target Price
- TLSA N/A
- HLVX $2.33
- AVG Volume (30 Days)
- TLSA 193.5K
- HLVX 420.9K
- Earning Date
- TLSA 07-22-2025
- HLVX 08-07-2025
- Dividend Yield
- TLSA N/A
- HLVX N/A
- EPS Growth
- TLSA N/A
- HLVX N/A
- EPS
- TLSA N/A
- HLVX N/A
- Revenue
- TLSA N/A
- HLVX N/A
- Revenue This Year
- TLSA N/A
- HLVX N/A
- Revenue Next Year
- TLSA N/A
- HLVX N/A
- P/E Ratio
- TLSA N/A
- HLVX N/A
- Revenue Growth
- TLSA N/A
- HLVX N/A
- 52 Week Low
- TLSA $0.63
- HLVX $1.34
- 52 Week High
- TLSA $1.91
- HLVX $2.17
- Technical
- Relative Strength Index (RSI)
- TLSA 46.42
- HLVX 63.53
- Support Level
- TLSA $1.43
- HLVX $2.06
- Resistance Level
- TLSA $1.81
- HLVX $2.17
- Average True Range (ATR)
- TLSA 0.09
- HLVX 0.08
- MACD
- TLSA -0.02
- HLVX 0.01
- Stochastic Oscillator
- TLSA 10.53
- HLVX 86.67
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.